LLLuke L. Lairson

Luke L. Lairson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luke L. Lairson has a total of 420 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct oligomeric assemblies of STING induced by non-nucleotide agonists

    by Anant Gharpure, Ariana Sulpizio, Johannes R. Loeffler, Monica L. Fernández-Quintero, Andy S. Tran, Luke L. Lairson, Andrew B. Ward

    STING plays essential roles coordinating innate immune responses to processes that range from pathogenic infection to genomic instability. Its adaptor function is activated by cyclic dinucleotide (CDN) secondary messengers originating from self (2’3’-cGAMP) or bacterial sources (3’3’-CDNs). Different classes of CDNs possess distinct binding modes, stabilizing STING’s ligand-binding domain (LBD) in either a closed or open conformation. The closed conformation, induced by the endogenous ligand 2’3’-cGAMP, has been extensively studied using cryo-EM. However, significant questions remain regarding the structural basis of STING activation by open conformation-inducing ligands. Using cryo-EM, we investigate potential differences in conformational changes and oligomeric assemblies of STING for closed and open conformation-inducing synthetic agonists. While we observe a characteristic 180° rotation for both classes, the open-LBD inducing agonist diABZI-3 uniquely induces a quaternary structure reminiscent but distinct from the reported autoinhibited state of apo-STING. Additionally, we observe slower rates of activation for this ligand class in functional assays, which collectively suggests the existence of a potential additional regulatory mechanism for open conformation-inducing ligands that involves head-to-head interactions and restriction of curved oligomer formation. These observations have potential implications in the selection of an optimal class of STING agonist in the context of a defined therapeutic application.


  • Insights into Free Drug Release from Efficacious N-Acyl O-Aminophenol Duocarmycin Prodrugs

    by Nilanjana Chakraborty, Jelena Momirov, Aleksandar Radakovic, Shreyosree Chatterjee, Aaron M. Kirchhoff, Anna-Lena Kolb, Thomas J. West, Brittany B. Sanchez, Salvador Martinez-Bartolome, Anthony Saviola, et al.

    Acyclic and cyclic N-acyl O-aminophenol prodrugs of duocarmycin analogues were reported as members of a unique class of reductively cleaved prodrugs that map seamlessly onto the duocarmycin family of natural products. Although these prodrugs were explored with the expectations that they may be cleaved selectively within hypoxic tumor environments that have intrinsically higher concentrations of reducing nucleophiles, the remarkable stability of some such prodrugs suggests another mechanism of free drug release is operative. The prototype of such chemically unreactive N-acyl O-aminophenol prodrugs is 1, which proved remarkably efficacious in vivo in vertebrate tumor models; was found to lack the toxicity that is characteristic of traditional chemotherapeutic drugs as well as the free drugs in the class (e.g., myelosuppression); and displayed a preferential site (intracellular), a slow and sustained rate, and a potentially unique mechanism of free drug release. Herein, we detail studies that provide insights into this stereoselective mechanism of free drug release. Combined, the results of the studies are consistent with an exclusive protein-mediated (enantio)selective activation and free drug release from prodrug 1 by N-O bond cleavage preferentially in cancer cell lines versus cultured normal human cell lines effected by a cytosolic cysteine-based enzyme and suggest that the activating protein is one that is selectively expressed, upregulated, or preferentially activated in cancer cell lines, potentially constituting a new oncology targeted precision therapy.


  • Open Access

    Induced cell phenotype activity recording of DNA-tagged ligands

    by Philipp N. Sander, Jared T. Gillen Miller, Luke L. Lairson

    A generalizable methodology for recording and retrieving the phenotype-inducing activity of DNA-encoded ligands.

  • Cladophorol-A is an inhibitor of cyclic GMP-AMP synthase

    by Mildred Kissai, Emily N. Chin, Francisco Martínez-Peña, Ariana Sulpizio, E. Paige Stout, Ippei Usui, Farhana Barmare, Brittany Sanchez, Eduardo Esquenazi, Robyn L. Stanfield, et al.


  • Top Cited Papers

    JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

    by Jaroslav Zak, Isaraphorn Pratumchai, Brett S. Marro, Kristi L. Marquardt, Reza Beheshti Zavareh, Luke L. Lairson, Michael B. A. Oldstone, Judith A. Varner, Livia Hegerova, Qing Cao, et al.

    Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti–PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of immune checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.


  • Human Hsp70 Substrate-Binding Domains Recognize Distinct Client Proteins

    by Andrew J. Ambrose, Christopher J. Zerio, Jared Sivinski, Xiaoyi Zhu, Jack Godek, Jonathan L. Sanchez, May Khanna, Rajesh Khanna, Luke Lairson, Donna D. Zhang, et al.

    The 13 Hsp70 proteins in humans act on unique sets of substrates with diversity often being attributed to J-domain-containing protein (Hsp40 or JDP) cofactors. We were therefore surprised to find drastically different binding affinities for Hsp70-peptide substrates, leading us to probe substrate specificity among the 8 canonical Hsp70s from humans. We used peptide arrays to characterize Hsp70 binding and then mined these data using machine learning to develop an algorithm for isoform-specific prediction of Hsp70 binding sequences. The results of this algorithm revealed recognition patterns not predicted based on local sequence alignments. We then showed that none of the human isoforms can complement heat-shocked DnaK knockout Escherichia coli cells. However, chimeric Hsp70s consisting of the human nucleotide-binding domain and the substrate-binding domain of DnaK complement during heat shock, providing further evidence in vivo of the divergent function of the Hsp70 substrate-binding domains. We also demonstrated that the differences in heat shock complementation among the chimeras are not due to loss of DnaJ binding. Although we do not exclude JDPs as additional specificity factors, our data demonstrate substrate specificity among the Hsp70s, which has important implications for inhibitor development in cancer and neurodegeneration.


  • A new road to STING activation

    by Ariana Sulpizio, Luke L. Lairson


  • Open Access

    Author Correction: Synthesis of portimines reveals the basis of their anti-cancer activity

    by Junchen Tang, Weichao Li, Tzu-Yuan Chiu, Francisco Martínez-Peña, Zengwei Luo, Christine T. Chong, Qijia Wei, Nathalia Gazaniga, Thomas J. West, Yi Yang See, et al.


  • Synthesis of portimines reveals the basis of their anti-cancer activity

    by Junchen Tang, Weichao Li, Tzu-Yuan Chiu, Francisco Martínez-Peña, Zengwei Luo, Christine T. Chong, Qijia Wei, Nathalia Gazaniga, Thomas J. West, Yi Yang See, et al.

    Marine-derived cyclic imine toxins, portimine A and portimine B, have attracted attention because of their chemical structure and notable anti-cancer therapeutic potential1,2,3,4. However, access to large quantities of these toxins is currently not feasible, and the molecular mechanism underlying their potent activity remains unknown until now. To address this, a scalable and concise synthesis of portimines is presented, which benefits from the logic used in the two-phase terpenoid synthesis5,6 along with other tactics such as exploiting ring-chain tautomerization and skeletal reorganization to minimize protecting group chemistry through self-protection. Notably, this total synthesis enabled a structural reassignment of portimine B and an in-depth functional evaluation of portimine A, revealing that it induces apoptosis selectively in human cancer cell lines with high potency and is efficacious in vivo in tumour-clearance models. Finally, practical access to the portimines and their analogues simplified the development of photoaffinity analogues, which were used in chemical proteomic experiments to identify a primary target of portimine A as the 60S ribosomal export protein NMD3.


  • Hydroxyproline metabolism enhances IFN-γ-induced PD-L1 expression and inhibits autophagic flux

    by Stephan H. Spangenberg, Amelia Palermo, Nathalia R. Gazaniga, Francisco Martínez-Peña, Carlos Guijas, Emily N. Chin, Markus M. Rinschen, Philipp N. Sander, Bill Webb, Laura E. Pereira, et al.